Male accessory gland infection/inflammation (MAGI) represents a nosographic category responsible for male infertility 1 with a prevalence ranging from 2% to 18% of infertile patients. 2 Indeed, according to the World Health Organization (WHO) criteria, MAGI can be established when a patient has oligo-, astheno-, and/or teratozoospermia associated with at least one factor A (history of genitourinary infection or physical signs) plus one factor B (abnormality of prostatic fluid), one factor A plus one factor C (ejaculate signs), one factor B plus one factor C, or two factors C. 3 Several mechanisms may contribute to the alteration of sperm parameters in patients with MAGI. These include the obstruction of the ejaculatory ducts, oxidative stress and imbalance of cytokines, impaired secretory capacity of the sex glands, and direct microbial damage. In this contest, ultrasound (US) characterization of patients with MAGI is routinely performed by evaluating prostate, seminal vesicles, and epididymis. However, in clinical practice the usefulness of US is controversial. Indeed, although their use is widespread, the specificity and sensitivity of this diagnostic tool are not considered very high for these specific conditions. 4 The American Institute of Ultrasound in Medicine (AIUM) suggests using transrectal ultrasound (TRUS) to evaluate the prostate and the seminal vesicles in all infertile patients. Other indications are represented by (a) echo-guided biopsy for prostate nodules suspected of malignancy by digital rectal examination or for elevated serum prostate-specific antigen (PSA) levels, and/or magnetic resonance imaging suggestive of prostate malignancy; (b) calculation of the prostate volume before surgical procedures and/or radiotherapy, and for the calculation of PSA density; (c) a guide for positioning the needles for radiotherapy; (d) evaluation of functional disorders associated with lower urinary tract symptoms (LUTS); (e) to study of